References
- Della Porta MG, Lanza F, Del Vecchio L. Flow Cytometry immunophenotyping for the evaluation of bone marrow dysplasia. Cytometry Part B. 2011;80B:201–211. doi: 10.1002/cyto.b.20607
- Rajab A, Porwit A. Screening bone marrow samples for abnormal lymphoid populations and myelodysplasia-related features with one 10-color 14-antibody screening tube. Cytometry Part B. 2015;88:253–260. doi: 10.1002/cyto.b.21233
- Stetler-Stevenson M, Yuan M. Myelodysplastic syndromes: the role of flow cytometry in diagnosis and prognosis. Int J Lab Hematol. 2009;31:479–483. doi: 10.1111/j.1751-553X.2009.01176.x
- Truong F, Smith BR, Stachurski D, et al. The utility of flow cytometric immunophenotyping in cytopenic patients with a non-diagnostic bone marrow: A prospective study. Leuk Res. 2009;33:1039–1046. doi: 10.1016/j.leukres.2009.01.012
- Malcovati L, Hellström-Lindberg E, Bowen D, et al. Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet. Blood. 2013;122:2943–2964. doi: 10.1182/blood-2013-03-492884
- Ogata K, Della Porta MG, Malcovati L, et al. Diagnostic utility of flow cytometry in low-grade myelodysplastic syndromes: a prospective validation study. Haematologica. 2009;94:1066–1074. doi: 10.3324/haematol.2009.008532
- Della Porta MG, Picone C, Pascutto C, et al. Multicenter validation of a reproducible flow cytometric score for the diagnosis of low-grade myelodysplastic syndromes: results of a European LeukemiaNET study. Haematologica. 2012;97:1209–1217. doi: 10.3324/haematol.2011.048421
- van Dongen JJM, Lhermitte L, Böttcher S, et al. Euroflow antibody panels for standardized n-dimensional flow cytometric immunophenotyping of normal, reactive and malignant leukocytes. Leukemia. 2012;26:1908–1975. doi: 10.1038/leu.2012.120
- Swerdlow SH, Campo E, Harris NL, et al. WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon: IARC Press; 2017.
- Kalina T, Flores-Montero J, van der Velden VH, et al. Euroflow standardization of flow cytometer instrument settings and immunophenotyping protocols. Leukemia. 2012;26:1986–2010. doi: 10.1038/leu.2012.122
- Bardet V, Wagner-Ballon O, Guy J, et al. Multicentric study underlining the interest of adding CD5, CD7 and CD56 expression assessment to the flow cytometric Ogata score in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms. Haematologica. 2015;100:472–478. doi: 10.3324/haematol.2014.112755
- Van de Loosdrecht AA, Westers TM, Westra AH, et al. Identification of distinct prognostic subgroups in low- and intermediate-1-risk myelodysplastic syndromes by flow cytometry. Blood. 2008;111:1067–1077. doi: 10.1182/blood-2007-07-098764
- Wells DA, Benesch M, Loken MR, et al. Myeloid and monocytic dyspoiesis as determined by flow cytometric scoring in myelodysplastic syndrome correlates with the IPSS and with outcome after hematopoietic stem cell transplantation. Blood. 2003;102:394–403. doi: 10.1182/blood-2002-09-2768
- Ogata K, Sei K, Saft L, et al. Revising flow cytometric mini-panel for diagnosing low-grade myelodysplastic syndromes: introducing a parameter quantifying CD33 expression on CD34+ cells. Leuk Res. 2018;71:75–81. doi: 10.1016/j.leukres.2018.07.009
- Porwit A, van de Loosdrecht A, Bettelheim P, et al. Revisiting guidelines for integration of flow cytometry results in the WHO classification of myelodysplastic syndromes proposal from the international/European LeukemiaNet working group for flow Cytometry in MDS. Leukemia. 2014;28:1793–1798. doi: 10.1038/leu.2014.191
- Westers T, Cremers E, Oelschlaegel U, et al. Immunophenotypic analysis of erythroid dysplasia in myelodysplastic syndromes. A report from the IMDSFlow working group. Haematologica. 2017;102:308–319. doi: 10.3324/haematol.2016.147835
- Cremers E, Westers T, Alhan C, et al. Implementation of erythroid lineage analysis by flow cytometry in diagnostic models for myelodysplastic syndromes. Haematologica. 2017;102:320–326. doi: 10.3324/haematol.2016.147843